WASHINGTON--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that its investigational agent, CleviprexTM (clevidipine butyrate) injectable emulsion was well tolerated in elderly patients and rapidly achieved and maintained blood pressure control in patients presenting to the emergency department or intensive care unit with acutely elevated blood pressure (n=27), according to a post-hoc analysis of the Phase 3 VELOCITY1 trial. VELOCITY was an open-label, single-arm, multi-center study in 126 emergency department patients presenting with acutely elevated blood pressure.
